全文获取类型
收费全文 | 1097篇 |
免费 | 115篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 46篇 |
妇产科学 | 9篇 |
基础医学 | 165篇 |
口腔科学 | 13篇 |
临床医学 | 104篇 |
内科学 | 231篇 |
皮肤病学 | 104篇 |
神经病学 | 138篇 |
特种医学 | 39篇 |
外科学 | 133篇 |
综合类 | 12篇 |
预防医学 | 67篇 |
眼科学 | 11篇 |
药学 | 80篇 |
中国医学 | 2篇 |
肿瘤学 | 55篇 |
出版年
2024年 | 3篇 |
2023年 | 15篇 |
2022年 | 8篇 |
2021年 | 27篇 |
2020年 | 14篇 |
2019年 | 20篇 |
2018年 | 49篇 |
2017年 | 41篇 |
2016年 | 23篇 |
2015年 | 39篇 |
2014年 | 32篇 |
2013年 | 46篇 |
2012年 | 66篇 |
2011年 | 73篇 |
2010年 | 31篇 |
2009年 | 27篇 |
2008年 | 79篇 |
2007年 | 76篇 |
2006年 | 67篇 |
2005年 | 69篇 |
2004年 | 59篇 |
2003年 | 51篇 |
2002年 | 51篇 |
2001年 | 43篇 |
2000年 | 55篇 |
1999年 | 42篇 |
1998年 | 9篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 11篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1974年 | 5篇 |
1973年 | 3篇 |
1971年 | 1篇 |
1967年 | 3篇 |
排序方式: 共有1216条查询结果,搜索用时 31 毫秒
1.
Tormo Nuria Giménez Estela Martínez-Navarro María Albert Eliseo Navalpotro David Torres Ignacio Gimeno Concepción Navarro David 《European journal of clinical microbiology & infectious diseases》2022,41(4):657-662
European Journal of Clinical Microbiology & Infectious Diseases - We compared the performance of an in-house-developed flow cytometry assay for intracellular cytokine staining (FC-ICS) and a... 相似文献
2.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
3.
4.
Alfredo Avellaneda Fernández álvaro Pérez Martín Maravillas Izquierdo Martínez Mar Arruti Bustillo Francisco Javier Barbado Hernández Javier de la Cruz Labrado Rafael Díaz-Delgado Pe?as Eduardo Gutiérrez Rivas Cecilia Palacín Delgado José Ramón Ramón Giménez Javier Rivera Redondo 《Atencion primaria / Sociedad Espa?ola de Medicina de Familia y Comunitaria》2009,41(10):e1-e5
5.
AIM: To determine the 2-year efficacy of continuous subcutaneous insulin infusion (CSII) following the current established criteria for funding of a National Health Service. METHODS: Longitudinal, prospective, observational unicentre study. Included in the study were 153 Type 1 diabetes (T1D) subjects, previously treated with multiple daily injections (MDI) of insulin, in whom CSII was started in accordance with the criteria for reimbursement of the Catalan National Health Service. At baseline, we recorded data on age, gender, duration of the disease, body mass index (BMI), insulin dose and indications for CSII. Glycated haemoglobin (HbA(1c)) and the frequency of hypoglycaemic events were used to assess glycaemic control. Quality of life was assessed using three different self-report questionnaires. After 24 months, these same items were remeasured in all subjects. Serious adverse events and injection-site complications were also recorded. RESULTS: In 96% of subjects, CSII indication included less than optimal glycaemic control using MDI. HbA(1c) fell from 7.9 +/- 1.3 to 7.3 +/- 1.1% (P < or = 0.001) after 24 months of CSII. Insulin requirements were significantly lower at the end of follow-up (0.55 +/- 0.21 U/kg body weight) in comparison with before use of CSII (0.70 +/- 0.20, P < or = 0.001). BMI increased from 24.0 +/- 3.1 to 24.4 +/- 3.2 kg/m(2) after 24 months (P < or = 0.025). The rate of episodes of diabetic ketoacidosis per year remained unchanged. Mild and severe hypoglycaemic episodes were significantly reduced. The scores in all subsets of the Diabetes Quality-of-Life (DQoL) questionnaire significantly improved after 24 months of CSII. CONCLUSIONS: CSII, commenced according to the criteria for a nationally funded clinical programme, improves glycaemic control and quality-of-life outcomes with fewer hypoglycaemic episodes in T1D subjects previously conventionally treated with MDI. 相似文献
6.
We report the identification of a new frameshift mutation (936delTA) in exon 6b of the CFTR gene. In the screening of 486 unrelated Spanish CF patients we found a patient homozygous for 936delTA (with consanguineous parents) and a patient heterozygous for delta F508 and 936delTA. Genotype-phenotype correlation studies showed that 936delTA is associated with pancreatic insufficiency and chronic pulmonary colonisation. 相似文献
7.
8.
9.
Ultrastructural changes associated with the inhibition of monocyte chemotaxis caused by products of axenically grown Entamoeba histolytica 总被引:1,自引:0,他引:1
J A Giménez-Scherer M G Pacheco-Cano E Cruz de Lavín P Hernández-Jáuregui M T Merchant R R Kretschmer 《Laboratory investigation; a journal of technical methods and pathology》1987,57(1):45-51
The supernatant fluid of axenically grown Entamoeba histolytica-HM1 significantly modifies the ultrastructural features associated with monocyte chemotaxis as assayed in Boyden chambers. This morphological evidence supports the existence of a factor, monocyte locomotion inhibitory factor (MLIF), produced by E. histolytica that inhibits the in vitro locomotion of human monocytes. None of the leucocyte-locomotion modifying drugs included in this study (i.e., cytochalasin-B, colchicine, vinblastine, and hydrocortisone) caused changes totally comparable with those induced by MLIF. The most striking feature was the increase of centriole-associated microtubules induced by MLIF and by cytochalasin-B. MLIF may inhibit monocyte locomotion by directly inducing excessive microtubule assembly, although a direct, if somewhat weak effect upon microfilaments cannot be excluded. The increase in microtubules could then represent a perhaps futile attempt of the microtubule organizing center to overcome the locomotion blockade that has occurred elsewhere in the cell. If active in vivo, MLIF may contribute to the paucity of inflammation in the advanced stages of invasive amebiasis, and consequently to the lack of scar tissue formation upon recovery from such lesions, as monocytes constitute an essential link to the healing process. 相似文献
10.